Guang Yang

12PUBLICATIONS
41CO-AUTHORS
Molecular targetsTumour immunologyMedical virologyMedical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 08, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.

|Mar 07, 2024
The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.

Hildo C Lantermans, Fangxue Ma, Annemieke Kuil

|Nov 18, 2021
Venetoclax in Previously Treated Waldenström Macroglobulinemia.

Jorge J Castillo, John N Allan, Tanya Siddiqi

|Sep 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.

Jorge J Castillo, Kirsten Meid, Joshua N Gustine

|Jul 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.

Steven P Treon, Kirsten Meid, Zachary R Hunter

|Jun 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.

Guang Yang, Jinhua Wang, Li Tan

Pageof 2

Frequent Collaborators

12 joint publications

Steven P Treon

10 joint publications

Zachary R Hunter

10 joint publications

Jorge J Castillo

5 joint publications

Andrew R Branagan